Basf Plant Science Gmbh

Galderma Holding Sa

Ipsen Biopharm Limited

Nestle Skin Health Sa

Ulf Stahl

Marit Lenman

Antoni Banas

Hans Ronne

Sten Stymne

Anders Dahlqvist

Anders Jarstad

Martijn Gipmans

Sebastiaan Mul

Sten Stymme

John Nolin

Anna Friis

Simon Aberg

Barbro Agren

Peter Frank

Andres Dahlqvist

Lena Nodqvist

Emilia Edstrom

Ann Gurell

Eva Wiberg

Andrew Pickett

The present technology relates to commercial-scale methods for purifying botulinum toxin compositions obtained from cell cultures. Purification methods according to the present disclosure are based on a series of filtration and chromatographic separation steps that produce a high-purity botulinum toxin composition, which comprises botulinum toxin protein molecules (˜150 kDa) in solution, which is free, essentially free, or substantially free of botulinum toxin complexes and animal products, and without precipitating or lyophilizing botulinum toxin protein molecules. The purification method according to the present disclosure uses no precipitation, lyophilization, or centrifugation steps, permitting production of highly pure, highly active, free botulinum toxin protein molecules (˜150 kDa) in solution, without the need for reconstitution by the end user.

Method of purifying botulinum toxin

The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.

Liquid neurotoxin formulation stabilized with tryptophan or tyrosine

The present invention relates to the isolation, identification and characterization of nucleotide sequences encoding an enzyme catalysing the transfer of fatty acids from phospholipids to diacylglycerol in the biosynthetic pathway for the production of triacylglycerol, to said enzymes and process for the production of triacylglycerols.

Process for the production of triacylglycerols

The invention relates to methods for increasing the oil content in plants, preferably in plant seeds, by expressing a polypeptide from yeast. The invention furthermore relates to expression constructs for expressing the yeast polypeptide in plants, preferably in plant seeds, the transgenic plants expressing the yeast polypeptide and to the use of said transgenic plants for the production of food, feeds, seed, pharmaceuticals or fine chemicals, in particular for the production of oils.

Use of a gene for increasing the oil content in plants

The present invention relates to the production of triacylglycerol in a transformed organism or host cell, by means of a nucleotide sequence fromwhereby said enzyme catalyzes the transfer of fatty acids from phospholipids to diacylglycerol in any acyl-CoA-independent reaction. The transformation of the organism or host cell results in increased oil content.

Methods of making triacylglycerol using phospholipid:Diacylglycerol acyltransferase

Growing community of inventors

Uppsala, Sweden

Ulf Stahl